Scientists Find Antibiotics in Scorpion Venom and Spicy Peppers

Researchers at Mexico's National Autonomous University (UNAM) have discovered that compounds from scorpion venom and habanero peppers can kill bacteria that resist standard antibiotics. The team, led by Lourival Domingos Possani Postay, found these natural compounds work against tuberculosis and a dangerous staph infection called MRSA according to Wired. The research involved collaboration with Richard Zare, a chemistry professor at Stanford University.

This work targets two serious infections. Tuberculosis kills thousands of people each year worldwide, and some strains no longer respond to common medications. MRSA—methicillin-resistant Staphylococcus aureus—is a bacteria found in hospitals that causes everything from skin infections to life-threatening blood infections.

Where the Idea Came From

Animals and plants that face constant threats from germs have evolved powerful chemical defenses. Scorpions, for instance, produce venom containing complex molecules that harm bacteria. The spicy compound in habanero peppers, called capsaicinoid, also kills bacteria naturally. The UNAM team extracted and modified these compounds using methods scientists have relied on for decades to turn natural products into medicines.

Several drugs already on the market come from venoms—including some derived from snake and spider venoms. The chemicals in scorpion venom tend to work by damaging bacterial cell walls and disrupting how bacteria survive. Capsaicinoids work similarly, punching holes in bacterial membranes.

The Challenge Ahead

Moving from laboratory success to a medicine people can actually take is difficult. Most venom-based drugs are peptides—long chains of amino acids—and peptides are hard to get into the body through a pill. They usually need to be injected instead. They can break down too quickly in the body, trigger immune reactions, or be expensive and complicated to manufacture at scale.

The Stanford partnership suggests the team has access to advanced tools needed to study these compounds carefully and figure out how to improve them. Making these drugs in large quantities will require synthesizing them in a lab rather than extracting them from actual scorpions, which would be impractical.

What Happens Next

If these compounds move forward, they would follow the standard path for new antibiotics: safety tests in animals, then three phases of human testing, overseen by regulatory agencies like the FDA. The process typically takes many years.

There is a broader context worth considering here. The antibiotics we rely on today came from discoveries made decades ago, but new antibiotic discovery slowed sharply in the 1980s and 1990s. The problem has gotten worse: bacteria develop resistance faster than pharmaceutical companies can develop new drugs. Many large drug makers stopped investing in antibiotics because the business case was weak—antimicrobial stewardship programs, which carefully limit antibiotic use to preserve their effectiveness, mean these drugs are prescribed less often than blockbuster medications. Recent policy changes, including government rewards and subscription models for antibiotic access, are trying to fix these economic problems.

For now, the UNAM findings add to growing evidence that nature's own defense systems might hold answers. Whether these specific compounds reach patients or not, the research shows one promising path forward at a time when medicine needs new tools to fight drug-resistant infections.